Dong-A ST Co., Ltd.

KOSE:A170900 Stock Report

Market Cap: ₩597.0b

Dong-A ST Past Earnings Performance

Past criteria checks 0/6

Dong-A ST's earnings have been declining at an average annual rate of -40.9%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 2.2% per year.

Key information

-40.9%

Earnings growth rate

-42.4%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate2.2%
Return on equity-3.8%
Net Margin-1.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 25
Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Recent updates

Is Dong-A ST (KRX:170900) A Risky Investment?

Oct 16
Is Dong-A ST (KRX:170900) A Risky Investment?

Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Aug 21
Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 25
Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 07
Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?

Apr 09
Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?

Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit

Mar 23
Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit

A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)

Mar 12
A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Feb 24
A Look At Dong-A ST's (KRX:170900) Share Price Returns

Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Feb 09
Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Jan 25
Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Jan 11
Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dec 25
Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Dec 22
Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

Dec 07
Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Nov 19
A Look At Dong-A ST's (KRX:170900) Share Price Returns

Revenue & Expenses Breakdown

How Dong-A ST makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A170900 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24675,406-6,678209,352130,185
31 Mar 24672,231-5,182205,005122,461
31 Dec 23663,98011,122201,466105,493
30 Sep 23637,0805,289200,69598,294
30 Jun 23632,15218,314198,59996,422
31 Mar 23626,24719,507200,57491,542
31 Dec 22635,39313,552197,81088,175
30 Sep 22634,15620,490194,18182,973
30 Jun 22624,34810,545195,45080,460
31 Mar 22608,56613,792187,34077,955
31 Dec 21593,22812,816184,48082,637
30 Sep 21568,5024,029179,01485,054
30 Jun 21562,255-3,362175,28782,528
31 Mar 21526,362-18,566170,43280,707
31 Dec 20586,72827,103163,68876,151
30 Sep 20614,77864,631164,36373,763
30 Jun 20630,90980,237163,80175,010
31 Mar 20670,90397,181166,65176,673
31 Dec 19612,31170,913170,37174,116
30 Sep 19594,54621,310171,05369,020
30 Jun 19573,4427,015170,13870,241
31 Mar 19574,39120,620170,93471,268
31 Dec 18567,4348,009169,85774,014
30 Sep 18574,26024,985172,91975,615
30 Jun 18577,49630,598171,10374,347
31 Mar 18557,65713,574167,28977,253
31 Dec 17555,027-5,396167,41478,698
30 Sep 17534,09613,724160,98678,563
30 Jun 17526,621-4,703167,14776,573
31 Mar 17546,731-13,140177,40273,076
31 Dec 16560,5352,623183,54669,539
30 Sep 16576,2579,384185,68164,882
30 Jun 16588,97327,434183,42265,218
31 Mar 16572,57743,069176,77859,654
31 Dec 15567,94047,495173,41757,366
30 Sep 15573,43442,755170,48860,126
30 Jun 15560,37242,855169,77758,283
31 Mar 15574,23537,791178,13460,518
31 Dec 14578,64037,412185,92163,602
30 Sep 14685,76324,320225,79672,004
30 Jun 14703,60720,485231,86674,319
31 Dec 13601,161-78,858197,51863,769

Quality Earnings: A170900 is currently unprofitable.

Growing Profit Margin: A170900 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A170900 is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.

Accelerating Growth: Unable to compare A170900's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A170900 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).

Return on Equity

High ROE: A170900 has a negative Return on Equity (-3.76%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y